What Antibiotics to Avoid If Allergic to Penicillin

Most people who carry a penicillin allergy label can safely take far more antibiotics than they think, including many drugs in the same broad family. The antibiotics that genuinely pose a cross-reactivity risk are a narrow subset of beta-lactams, primarily certain first-generation cephalosporins that share a specific chemical side chain with penicillin. Carbapenems and the monobactam aztreonam carry little to no meaningful cross-reactivity, and even many cephalosporins are well tolerated. The real story here is less about what to avoid and more about how an allergy label, often inaccurate in the first place, funnels people toward second-choice antibiotics that work less well and carry their own risks.

The Side Chain That Actually Matters

Penicillins and cephalosporins both belong to a class called beta-lactams, named after a shared ring structure in the molecule. For years, doctors assumed this shared ring was the reason someone allergic to penicillin might also react to a cephalosporin. That thinking has largely been replaced. Research now points to a different part of the molecule, a chemical appendage called the R1 side chain, as the main driver of cross-reactivity between these drugs. When a cephalosporin has an R1 side chain that closely resembles penicillin’s, the immune system is more likely to mistake one for the other and mount a reaction.

This side-chain model has held up well. An Australian cohort study confirmed that people with a proven cephalosporin allergy showed cross-reactivity within drugs that share the same R1 side chain group, but showed no evidence of broader cross-reactivity across unrelated cephalosporins.

1PubMed Central. Cephalosporin allergy: R1 side-chain and penicillin cross-reactivity patterns in an Australian cohort

What does this mean in practice? A few first-generation cephalosporins, such as cephalexin and cefazolin, have side chains that overlap with penicillin or amoxicillin. These are the drugs most likely to trigger a reaction in someone with a confirmed penicillin allergy. A literature review found that penicillins showed meaningful cross-reactivity with first-generation cephalosporins but negligible cross-reactivity with second-generation cephalosporins.

2PubMed. The use of cephalosporins in penicillin-allergic patients: a literature review

Cephalosporins You Can Likely Still Take

If a cephalosporin’s R1 side chain does not resemble penicillin’s, the risk of a cross-reaction drops dramatically. Second-, third-, and fourth-generation cephalosporins tend to have distinct side chains, and studies consistently show they are well tolerated in penicillin-allergic patients. A study of over 200 people with confirmed delayed-type penicillin hypersensitivity found that all had negative skin test responses to cefuroxime and ceftriaxone, and every patient who underwent a drug challenge tolerated those cephalosporins without a reaction.

3Journal of Allergy and Clinical Immunology. Safety of cephalosporins and aztreonam in patients with penicillin allergy and delayed-type hypersensitivity

A large real-world implementation study drove the point home. After a hospital system relaxed its cross-reactivity alerts to allow more cephalosporin prescribing for penicillin-allergic patients, cephalosporin use rose by about 8 percent with no significant increase in adverse events and no severe reactions attributable to cross-reactivity.

4PubMed. Assessing the safety of increased outpatient cephalosporin use following the modification of penicillin allergy cross-reactivity alerts

Despite this reassuring data, cephalosporins remain widely over-avoided. Research from a US cohort found that administering cephalosporins appeared safe even in the highest-risk patients with verified penicillin allergy, and the authors argued that these drugs are avoided far more often than the evidence warrants.

5The Journal of Allergy and Clinical Immunology: In Practice. Why Was There Ever a Warning Not to Use Cephalosporins in the Setting of a Penicillin “Allergy”?

The practical takeaway: if your doctor needs to prescribe a cephalosporin, the specific drug matters more than the generation label. Your clinician should check whether the cephalosporin in question shares a side chain with the penicillin-type drug that caused your reaction.

6PubMed Central. Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity

Carbapenems and Aztreonam

Carbapenems (meropenem, imipenem, ertapenem) are heavy-hitter antibiotics often reserved for serious infections. They share the beta-lactam ring with penicillin, so doctors historically hesitated to use them in penicillin-allergic patients. The evidence, however, shows very low cross-reactivity. A meta-analysis pooling data from over a thousand penicillin-allergic patients found the risk of reacting to any carbapenem was under 1 percent.

7PubMed. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses

An earlier single-center study did find a somewhat higher reaction rate, with roughly 9 percent of penicillin-allergic patients developing some hypersensitivity to carbapenems compared to about 4 percent of non-allergic patients.

8PubMed. Is it safe to use carbapenems in patients with a history of allergy to penicillin?

The discrepancy likely reflects differences in how allergy was confirmed and how reactions were defined. The pooled data from larger analyses is more reassuring, and most allergy specialists now consider carbapenems acceptable for penicillin-allergic patients when the clinical situation calls for them.

Aztreonam sits in its own class: the monobactams. Unlike penicillins and cephalosporins, aztreonam has a single-ring beta-lactam structure rather than a fused two-ring structure. Studies going back to the 1980s showed no cross-reactivity between penicillin-specific antibodies and aztreonam.

9PubMed. Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects

Aztreonam does share an identical side chain with the cephalosporin ceftazidime, which in theory could create a link between those two drugs. But a case series found that all patients with a ceftazidime allergy tolerated aztreonam without any evidence of cross-reactivity, likely because the distinct monobactam ring protects against cross-recognition by the immune system.

10Journal of Antimicrobial Chemotherapy. Re-evaluating aztreonam and ceftazidime hypersensitivity: fraternal not identical twins

For patients with confirmed penicillin allergy who need a beta-lactam, aztreonam is considered one of the safest choices available, though its spectrum of activity is narrow (mostly gram-negative bacteria), which limits its clinical usefulness.

Most Penicillin Allergy Labels Are Wrong

Here is the part that surprises most people: the overwhelming majority of those who believe they are allergic to penicillin are not. An emergency department study that skin-tested 150 patients reporting penicillin allergy found that over 91 percent tested negative, meaning they could tolerate penicillin without any immune reaction.

11PubMed Central. The Use of Penicillin Skin Testing to Assess the Prevalence of Penicillin Allergy in an Emergency Department Setting

In children, the picture is similar. Research from two large pediatric networks found that fewer than 5 percent of children labeled as penicillin-allergic actually had a true immune-mediated allergy on formal testing.

12PubMed Central. Factors Associated With Penicillin Allergy Labels in Electronic Health Records of Children in 2 Large US Pediatric Primary Care Networks

Why the discrepancy? Many “allergies” originate from a childhood rash that was actually caused by the underlying viral infection, not by the antibiotic. A common scenario involves a child given amoxicillin during an illness caused by Epstein-Barr virus (the virus behind mono). The virus itself, or the combination of virus and drug, triggers a rash that gets blamed on the antibiotic, and the allergy label sticks for life.

13PubMed Central. Amoxicillin-Induced Hypersensitivity Versus Viral Exanthem in Epstein-Barr Virus Infection: A Paediatric Case Series

Other labels arise from non-allergic side effects like stomach upset or headaches that get recorded as “allergy” in the medical chart. Over time, even true allergies can fade: the immune sensitivity that produced a reaction at age five may no longer exist at age thirty. The result is a massive population walking around with a label that restricts their treatment options for no good reason.

What Happens When You Avoid Penicillins Unnecessarily

An inaccurate allergy label is not harmless. When penicillins and related beta-lactams are off the table, doctors turn to alternatives that tend to be broader in spectrum, more expensive, and sometimes less effective for the infection being treated. This has measurable consequences.

Penicillin allergy labels are associated with increased use of broad-spectrum antibiotics, which in turn drives antibiotic resistance, a problem that affects not just the individual patient but the wider community.

14PubMed Central. The challenge of de-labeling penicillin allergy

A Chinese population-based study found that patients with COPD who carried a penicillin allergy label received more broad-spectrum antibiotics and had a roughly 40 percent higher risk of disease flare-ups compared to unlabeled patients.

15PubMed Central. Penicillin Allergy Labels, Broad-Spectrum Antibiotic Use, and Chronic Obstructive Pulmonary Disease Exacerbations: A Population-Based Cohort Study from China

In surgery, the stakes are particularly clear. A penicillin allergy label has been linked to about a 50 percent increased odds of surgical site infection, entirely attributable to the substitution of second-line antibiotics like clindamycin or vancomycin for the preferred beta-lactam prophylaxis.

16PubMed Central. Understanding Penicillin Allergy, Cross-reactivity, and Antibiotic Selection in the Preoperative Setting

Pregnancy raises its own concerns. About 8 percent of pregnant people report a penicillin allergy, and the alternative antibiotics they receive tend to be costlier and less effective for conditions where penicillins are the gold standard, such as Group B streptococcus prevention and syphilis treatment.

17PubMed Central. Society for Maternal-Fetal Medicine Special Statement: Assessment and management of reported penicillin allergy in pregnancy

Getting Tested and Removing the Label

If you have a penicillin allergy on your chart, getting it formally evaluated can open up your treatment options significantly. The standard approach has two tiers: skin testing and oral challenge.

Penicillin skin testing involves pricking or injecting small amounts of penicillin breakdown products into the skin and watching for a reaction. When both the major and minor determinants of penicillin are tested, a negative result carries a predictive value of roughly 97 to 99 percent, meaning almost everyone who tests negative will tolerate penicillin without a problem.

18Annals of Allergy, Asthma & Immunology. Penicillin skin testing in the evaluation and management of penicillin allergy

However, the skin test itself is not perfect. A meta-analysis found that its sensitivity sits around 31 percent, meaning it misses a substantial fraction of truly allergic patients. Specificity is high, so a positive result is almost certainly real, but a negative result occasionally misses someone who would react.

19PubMed Central. Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis

Minor determinant testing adds value here. In one inpatient study of 528 patients, about 64 percent of those who tested positive reacted to a compound other than the major determinant, underscoring why testing with both major and minor determinants gives a more complete picture.

20PubMed. Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation

An even simpler approach is gaining ground: the direct oral challenge, where a patient simply takes a dose of amoxicillin under medical supervision and is monitored for a reaction. For people whose reported allergy was mild (a rash, stomach upset, or vague symptoms from years ago), multiple studies show this is safe without doing skin testing first. A randomized trial (the PALACE trial) found that going straight to an oral challenge was as safe as the traditional pathway of skin testing followed by a challenge, with no serious adverse events.

21Open Forum Infectious Diseases. Amoxicillin Direct Oral Challenge in Hospitalized Patients With High-Risk Allergic Reactions, in a Pharmacist-Directed Program

An Australian hospital study confirmed that oral amoxicillin challenge without prior skin testing was safe and feasible for low-risk inpatients.

22PubMed. Oral amoxicillin challenge for low-risk penicillin allergic patients

Pediatric studies echo this finding, with about 97 percent of children tolerating the challenge and the few reactions being mild, delayed rashes.

23PubMed. Delabelling suspected amoxicillin allergy in pediatric patients using oral challenge: a retrospective study from Northwestern Ontario

Even patients with a history of higher-risk reactions like hives, swelling, or anaphylaxis may be candidates for direct oral challenge once ten or more years have passed from the original reaction, though this should happen in a supervised clinical setting with resuscitation equipment available.

21Open Forum Infectious Diseases. Amoxicillin Direct Oral Challenge in Hospitalized Patients With High-Risk Allergic Reactions, in a Pharmacist-Directed Program

When You Truly Cannot Take Any Beta-Lactam

There is a small group of people for whom beta-lactam avoidance is absolutely the right call. Anyone who has had a severe cutaneous adverse reaction, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS), should not be challenged or re-exposed to the drug that caused it. These are delayed hypersensitivity reactions that can be life-threatening. Among the severe cutaneous reactions caused by beta-lactam antibiotics, toxic epidermal necrolysis carries the worst prognosis, with over a quarter of patients experiencing serious complications or death.

24World Allergy Organization Journal. Clinical characteristics of severe cutaneous adverse reactions caused by beta-lactam antibiotics

These reactions are rare but they are a hard line. The standard de-labeling approaches, skin testing and oral challenges, do not apply to this group. The immune memory driving these reactions is different from the antibody-mediated pathway behind typical penicillin allergy, and re-exposure can trigger a recurrence. If you experienced widespread blistering of skin or mucous membranes, high fever with rash and organ involvement, or were hospitalized for a drug reaction, your allergy label should stay.

25PubMed Central. The assessment of severe cutaneous adverse drug reactions

For these patients, the antibiotic alternatives that work depend entirely on the type of infection. Options include fluoroquinolones, macrolides (like azithromycin), trimethoprim-sulfamethoxazole, and others chosen based on the specific bacteria involved. An allergist can help map out which beta-lactams, if any, might be safe based on side-chain analysis, since even in this group, cross-reactivity does not extend universally across every beta-lactam.

Desensitization for Situations with No Good Alternative

Sometimes penicillin is the only drug that will work, and the patient is genuinely allergic to it. The textbook example is a pregnant woman with syphilis: penicillin is the only antibiotic proven to treat syphilis in pregnancy, and the only structurally unrelated alternative, doxycycline, carries risks to the developing fetus.

26PubMed Central. Antimicrobial Desensitization: A Review of Published Protocols

In these cases, desensitization is an option. The process involves giving the patient extremely small, incrementally increasing doses of the drug over hours, typically in an intensive care or closely monitored setting. This temporarily coaxes the immune system into tolerating the drug at its full therapeutic dose. Desensitization does not cure the allergy. It creates a window of tolerance that lasts only as long as the drug is being administered. If the patient stops and needs the drug again later, the process must be repeated from scratch. It is not risk-free, but it is well established for immediate-type allergic reactions and is regularly carried out in hospitals when there is no viable alternative.

The Alert Fatigue Problem

A significant barrier to better prescribing sits inside the electronic health record. When a penicillin allergy is on file, prescribing software fires alerts every time a doctor tries to order a beta-lactam, even when the specific drug in question has no meaningful cross-reactivity. Over time, clinicians become so accustomed to overriding or being stopped by these alerts that they give up and simply choose a non-beta-lactam. This alert fatigue leads to reflexive avoidance rather than thoughtful assessment.

27PubMed. Addressing the Challenges of Penicillin Allergy Delabeling With Electronic Health Records and Mobile Applications

Hospitals that have revised their alert systems to reflect current cross-reactivity evidence have seen encouraging results. When one system modified its alerts to stop blocking cephalosporins in penicillin-allergic patients, prescribing of cephalosporins went up, use of second-line agents went down, and there was no increase in adverse events.

4PubMed. Assessing the safety of increased outpatient cephalosporin use following the modification of penicillin allergy cross-reactivity alerts

This kind of system-level change, updating allergy records, refining clinical decision support tools, and making de-labeling programs routine, may end up doing more to fix the penicillin allergy problem than any individual prescribing decision. If you carry a penicillin allergy label and have never been formally tested, bringing it up with your doctor is one of the more useful things you can do for your own future medical care.